INTRODUCTION

Polycystic ovary syndrome (PCOS) is characterized to be a metabolic syndrome which may include hyperinsulinemia, hyperlipidemia, diabetes mellitus, and possible cardiac disease, as well as high androgen levels, anovulation, infertility, endometrial cancer, and obesity (Norman, 2002; Lobo and Carmina, 2000). The estrogens stimulate luteinizing hormone (LH) and inhibit follicle-stimulating hormone (FSH) secretion, contributing to granulosa cell and theca cell (TC) hyperplasia in obese women with PCOS; this would increase androgen synthesis and reinforcing this cycle of hyperestrogenemia-hyperandrogenemia in obese women with this pathology which is serving as substrates for extraovarian aromatization (Pasquali and Casimirri, 1993). Feedback disturbances in the hypothalamus-hypophysis-ovary axis are another typical feature of PCOS (Blank et al., 2006). That they suppress endogenous FSH levels, thereby preventing maturation of the small “healthy” follicles (Chavez-Ross et al., 1997). Ovary produces inappropriate levels of estradiol (and progesterone) for their size (Willis et al., 1998). Higher levels of gonadotropin-releasing hormone (GnRH) induce greater androgen synthesis in ovarian TC due to an increased frequency and amplitude of GnRH and LH pulsatile secretion (Blank et al., 2009).

In PCOS, the ovaries may not release follicle regularly or they may not release health follicle. High levels of anti-Mullerian hormone are appeared to play an important role in long-term disruption of ovarian physiology in women with PCOS (Karkanaki et al., 2011). Elevated levels AMA concentration associated with infertility (Pierre et al., 2013). Infertility is currently affects the women aged 20–44 years, as it one of the most alerting associated morbidity (Mascarenhas et al., 2012). Failure to become pregnant without using contraception after 1 year of regular intercourse in women <35 years and after 6 months in women >years is called infertility (Practice Committee of the American Society for Reproductive Medicine, 2008).

Progesterone is essential for the implantation and maintenance of early human pregnancy. The follicular phase of the menstrual cycle is estrogen dominated, while the luteal phase of the menstrual cycle is progesterone dominated (Cameron et al., 1996). Progesterone is produced after ovulation by the corpus luteum (sack that the egg comes from) and dominates the second half
of the cycle (luteal phase). In many species, a decrease in circulating progesterone at the time of fertilization is sufficient to delay implantation so the progesterone has a major role in the endometrium in preparation for implantation of a fertilized ovum (Rothchild, 1983). In women with PCOS, ovarian follicles arrest in a state of pre-ovulation; this state of arrest is caused primarily by an overabundance of androgens, which impedes follicle growth and ovulation. Current opinion suggests that insulin resistance (IR) is the culprit because it is observed in many women with PCOS (Dunaif et al., 1989; Johnson, 2014). Causes an abnormal response in the ovary that results in an increase in the amount of circulating androgens is IR that leads to hyperandrogenism (Fritz et al., 2011).

Female infertility can result from age, physical problems, hormone abnormality, and lifestyle or environmental factors. Most cases of infertility in women result from problems with producing eggs. In premature ovarian failure, the ovaries stop functioning before natural menopause. Therefore, considering the severe consequences, PCOS exerts on the health and lifestyle of the affected women, it is most importance to unravel the intricate pathophysiologic cross-talk among PCOS, IR, and obesity. Aside from disturbances in insulin physiology, obesity implies thorough alterations in steroid hormone metabolism, essentially summarized as increased concentrations of nearly all of these messengers. GnRH agonist (GnRHa) is effective even severe IR in women with PCOS who are unresponsive to oral contraceptive; the GnRHa suppresses pituitary hormones, decreases androgen and estradiol secretion, and improves severe forms of hirsutism (Cristello et al., 2005).

**Aim of Study**
The aim of the study is to decrease percentage of infertility in women with polycystic ovarian syndrome and study the effects of various duration of dose hormone recombinant FSH (rFSH) on ovary and women hormone.

**MATERIALS AND METHODS**
This study was carried out from 2016 to 2017 and this was included 40 women with an ovulatory infertility due to PCOS were taken randomly which was diagnosed by gynecologist in the Erbil Maternal Hospital, the mean (± SE) age of the patients was 28.9 ± 0.8 years, and their mean duration of infertility was 2.2 ± 0.2 years. All patients had both ovaries and had to ovulate with clomiphene citrate at doses of 100 mg/day after regulation menstruation cycle with oral contraceptive Progyluton. Forty women healthy were taken in this study as a control.

**Protocol Treatment**
Women infertile with PCOS were divided in two groups, Group one was treated with low-dose (Gonal F) FSH subcutaneously injection 75 IU for 3 days while Group two treated with high-dose rFSH subcutaneously injection 75 IU for 5 days. Sonography was done for two groups to determined size follicles in ovaries at on human chorionic gonadotropin (HCG) day and check serum level hormone FSH, LH, progesterone, and testosterone. These tests were done by Minivid apparatus and used Minivid kits.

**Blood Sample**
Blood samples were drawn from each patients with PCOS, and the serum was utilized for determination level hormones, follicle stimulation hormone, LH, progesterone, and testosterone. These investigations repeated after treated with hormone replacement on HCG.

Patients with irregular menstruation by lack hormone progesterone level are participating in this study and any other defects infertility women with PCOS which are excluded.

**Statistical Analysis**
Analysis of variance (ANOVA) was used to find the differences between groups. The Duncan test was applied to determined factor effect. *P* value was considered significant, when it is less than 0.05.

**RESULTS**
The result of our study was revealed that the serum levels (FSH, LH, and progesterone) of women with PCOS in Group 1 (after treatment with low dose 75 IU of rFSH) were significantly changed on day HCG while testosterone level was decrease but no significant change at *P* > 0.05 when compared with control group, as shown in Table 1.

After treatment, 20 infertile women with PCOS (Group 2) with long-term therapy (75 IU rFSH), the serum levels (FSH and progesterone) were significantly increase but the serum level LH was significant decrease while testosterone was no significant change at *P* > 0.05 when compared with before treated, as shown in Table 2.

As shown in Table 3, the women with PCOS treated short term by 75 IU that pregnancy rate was high and ovary hyperstimulation syndrome was less occurs in Group 1 as compared with Group 2 women with PCOS with long-term therapy.

**DISCUSSION**
Polycystic ovary disease (PCOS) is a hormonal imbalance in women that are thought to be one of the leading causes
of female infertility (Hack et al., 1972). PCOS causes of an ovulatory infertility approximately 75% of cases (Goldenberg and Glueck, 2008). The result of this study was showed management women infertility with polycystic ovarian syndrome which is characterized hormone disturbance progesterone, testosterone, FSH, and LH compared with control. This oligomenorrhea was treated by oral contraceptive which is contained progesterone and estrogen. Menstrual irregular management using progesterone replacement is beginning to treat infertility, it is similar to studies along with women PCOS complaints of menstrual irregularity, the often chronic an ovulation that is associated with PCOS can increase patients infertility and inhibited endometrial proliferation. Using either cyclic progestin or a low-dose contraceptive was containing estrogen and progestin (Gorry et al., 2006). The primary recommended treatment option for PCOS-related menstrual disorders and improved menstrual regularity with low-dose contraceptive (Badawy and Elnashar, 2011). PCOS affects approximately 5–10% of women of reproductive age and is one of the most common causes of anovulatory infertility (ACOG Committee on Practice Bulletins – Gynecology ACOG Practice Bulletin No 108. 2009). Menstrual disruption typically manifests in PCOS, ranging from oligomenorrhea to amenorrhea.

Both groups (1 and 2) were associated with low FSH (3.90 ± 0.52), (3.89 ± 0.50) and high level LH (14 ± 2.41), (13.48 ± 1.05), as shown in Tables 1 and 2, hormonal abnormality in women with PCOS leads to an ovulation and infertility. This is right with these studies elevated LH concentrations frequently are encountered in patients with PCOS and different studies have linked excessive LH secretion with detrimental effects on reproductive function, such as irregular menstrual cycles, an ovulation, infertility, and miscarriage (Hopkinson et al., 1998).

In our study women infertile with PCOS associated with hyperandrogenism, which lead imbalance serum hormones that elevated LH and decrease growth follicles in ovaries which lead to infertility. This result was coherent that Gonadotropin especially elevated in luteinizing hormone (Brothers., et al 2010). Polycystic ovary syndrome accounts for more than 75% of cases of anovulatory infertility. The mechanism of anovulation is uncertain but there is evidence that arrested antral follicle development is associated with the abnormal endocrine profile, in particular the interaction of insulin and LH on granulosa cell differentiation.(Gorry., et al 2006).

In Tables 1 and 2, women with polycystic ovarian syndrome were associated with increase serum level testosterone or androgen hormone this is right with these studies more than 80% of women presenting with symptoms of androgen excess have PCOS (Qiao and Feng, 2010). Hirsutism is a common clinical presentation of hyperandrogenism occurring in up to 70% of women with PCOS (Filicori, 1999).

Results revealed non-significant statistical differences ($P > 0.005$) at high-dose and low-dose recombinant FSH subcutaneous injection on pregnancy rate in PCOS patients. However, management anovulatory in Group one women with PCOS by low-dose rFSH was better than high-dose rFSH in Group two, but in Group one,
ovarian hyperstimulation syndrome (OHSS) less occurs and pregnancy rate was high. This was confirmed with studies the goal of FSH administration for ovulation induction which is the development of a single follicle resulting in a singleton live birth. Risks associated with ovulation induction include OHSS and pregnancy with multiples. Because women with PCOS are very sensitive to the effects of FSH, a low-dose step-up protocol is recommended (Taymar, 1996; Thessaloniki, 2008). For women with PCOS, treatment a low-dose regimen of gonadotropins rFSH has almost completely eliminated the complication of OHSS and maintaining an acceptable pregnancy rate (Christin-Maitre and Hugues, 2003).

**CONCLUSION**

According to this study, we conclude that decreased infertility women with polycystic ovarian syndrome after treated with low-dose recombinant FSH therapy associated increase pregnancy rate and less ovary hyperstimulation syndrome OHSS than high-dose recombinant FSH therapy.

**RECOMMENDATIONS**

1. Management infertility in women with polycystic ovarian syndrome by other hormone drugs
2. Comparative study with women polycystic ovarian syndrome treated by metformin and with weight by exercise
3. Comparative study between infertility women with polycystic ovarian syndrome treated by hormone with ovary drill by laparoscopy.

**REFERENCES**


